Schlieren, Switzerland
DiNAQOR AG completed construction in July of 2020 on a 9,687-sf R&D center in Schlieren, Switzerland. Located in the Bio-Technopark Schlieren-Zürich, the BSL-2 facility will enable DiNAQOR to fast-track the development of its human-induced pluripotent stem cells (iPSC) and engineered heart tissue platform. Accelerating the creation of next-generation genetic medicine methodologies, the project also provides sophisticated infrastructure to further optimize the company's proprietary locoregional heart perfusion approach. DiNAQOR will occupy the facility in fall of 2020.
Source
